ライフサイエンスコーパス: serum insulin

1 se and serum C-reactive protein but not with serum insulin.

2 te or cocoa due to significant reductions in serum insulin.

3 ter glucose dosing and varies inversely with serum insulin.

4 /- 1.2 compared with 4.7 +/- 1.6 mmol/L) and serum insulin (138 +/- 76 compared with 136 +/- 116 pmol

5 roughout (5.3 +/- 0.3 micromol/g wet wt when serum insulin = 16 +/- 7 pmol/l vs. 5.5 +/- 0.3 micromol

6 /- 0.5 compared with 4.9 +/- 0.9 mmol/L) and serum insulin (244 +/- 93 compared with 151 +/- 57 pmol/

7 red with -0.9 +/- 16.6 mg/dL; P < 0.001) and serum insulin (-3.08 +/- 6.62 compared with +1.34 +/- 6.

8 mol/l vs. 5.5 +/- 0.3 micromol/g wet wt when serum insulin = 668 +/- 81 pmol/l, P = NS).

9 For a one SD higher level of serum insulin (7.14 micro U/ml), C-peptide (0.45 Deltamo

10 euglycemic-hyperinsulinemic clamps (n = 10, serum insulin = 89 +/- 7 microU/dl), PAI-1 in blood incr

11 tically elevated levels of blood glucose and serum insulin accompanied by extreme insulin resistance.

12 arotenoids were inversely related to fasting serum insulin after adjustment for confounders (p < 0.05

13 activity, increased thermogenesis, and lower serum insulin, all of which correlate with a higher leve

14 , and this effect was associated with higher serum insulin, amylin, and glucagon-like peptide 1 level

15 intravenous insulin to mimic the changes in serum insulin and blood glucose levels observed after in

16 related with adult growth, liver weight, and serum insulin and cholesterol levels.

17 ectomy reduced the levels of plasma glucose, serum insulin and corticosterone, and food intake toward

18 glycemic control, corresponding to increased serum insulin and enhanced glucose-stimulated insulin re

19 Serum insulin and estradiol values measured previously w

20 reases of body weight, body fat content, and serum insulin and free fatty acid (FFA) levels compared

21 Serum insulin and glucose concentrations during the oral

22 To characterize 7-year changes in fasting serum insulin and glucose concentrations, the authors an

23 to less weight loss and smaller decreases in serum insulin and HOMA-IR (all P </= 0.02 in an additive

24 oss (P=0.008) but became null for changes in serum insulin and HOMA-IR resulting from weight regain.

25 challenge, and induction of higher levels of serum insulin and IGF1 were observed when diabetic mice

26 e of the normal inverse relationship between serum insulin and IGFBP-1 levels in glucoregulation and

27 rosin A significantly reversed the increased serum insulin and insulin resistance (IR) in dexamethaso

28 abetes, soy protein has been shown to reduce serum insulin and insulin resistance.

29 Serum insulin and plasma flow areas under the curve (AUC

30 Serum insulin and plasma flow areas under the curve (AUC

31 Others reported inverse relations between serum insulin and sex hormone-binding globulin (SHBG).

32 nificant correlation between the decrease in serum insulin and the increase in urinary NO(X) (r2=0.68

33 Serum, insulin and insulin-like growth factor, but not e

34 t-1 cells blocked DNA synthesis initiated by serum, insulin and various purified growth factors, but

35 lucose, blood pressure, body mass index, and serum insulin) and incident diabetes differed by case de

36 um biomarkers of islet distress (e.g., acute serum insulin) and inflammation (e.g., leptin and alpha2

37 tokinin, peptide YY, ghrelin, blood glucose, serum insulin, and appetite were measured during 60-min,

38 men-by-time interactions for plasma glucose, serum insulin, and blood lactate concentrations.

39 erol intake and risk of T2D, plasma glucose, serum insulin, and C-reactive protein were mainly nonsig

40 Blood glucose, plasma total GLP-1 and GIP, serum insulin, and gastric emptying were determined.

41 es, and free fatty acids, but blood glucose, serum insulin, and glucose tolerance are normal.

42 All mice were evaluated for blood glucose, serum insulin, and glucose tolerance up to postoperative

43 (P < 0.05) positively with serum C-peptide, serum insulin, and glycated hemoglobin and inversely wit

44 y significantly decreased the blood glucose, serum insulin, and glycated hemoglobin levels.

45 is reduced 52% (p < 0.001) despite decreased serum insulin, and homeostasis model assessment insulin

46 insulin tolerance, higher levels of fasting serum insulin, and lower pancreatic insulin content.

47 mal protein S6 could be rapidly activated by serum, insulin, and phorbol ester in transiently transfe

48 tion at the TR-->FO checkpoint, 2) abrogated serum insulin autoantibodies, 3) reduced the severity of

49 18 mmol l(-1), P = 1.1 x 10(-6)) and fasting serum insulin (beta = -8.3 pmol l(-1), P = 0.0014), and

50 eta = 3.8 mmol l(-1), P = 2.5 x 10(-35)) and serum insulin (beta = 165 pmol l(-1), P = 1.5 x 10(-20))

51 The detection of picomolar levels of serum insulin binding to the surface antibody was achiev

52 iastolic indexes included sex, age, baseline serum insulin, blood pressure, and heart rate.

53 y after an overnight fast for measurement of serum insulin, C-peptide, and glucose.

54 d 2.65 (95% CI, 1.25 to 5.62; P = 0.008) for serum insulin, C-peptide, HbA1c levels, and HOMA-insulin

55 ogressively higher with increasing levels of serum insulin, C-peptide, HbA1c, and HOMA-insulin resist

56 nse to glucose, and determination of fasting serum insulin, C-peptide, triglyceride, and free fatty a

57 e, day 1, and week 4, respectively), fasting serum insulin (CDP571: 21.2 +/- 2.8, 21.0 +/- 2.8, 24.8

58 Deletion studies showed that serum, insulin, cholera toxin, and FGF7 were necessary f

59 Serum insulin, cholesterol, and triglyceride levels were

60 lin-dependent PKB/Akt phosphorylation, lower serum insulin, cholesterol, and triglyceride levels, as

61 +/- 10.1 vs. +1.8 +/- 8.1 mg/dL, P < 0.001), serum insulin concentration (-2.1 +/- 6.5 vs. +5.7 +/- 1

62 The serum insulin concentration also was slightly elevated a

63 Fasting serum insulin concentration and the insulin sensitivity

64 Serum insulin concentration at 30 minutes after a 75-g d

65 Serum insulin concentration increased 20-fold during ins

66 Serum insulin concentration increased more for C+P than

67 Serum insulin concentration increased to maximal on day

68 An increase in serum insulin concentration of > 200 pM for > 24 h was n

69 Serum insulin concentration, net forearm carnitine balan

70 s with T2DM treated with DXM showed enhanced serum insulin concentrations and glucose tolerance.

71 d at 52 weeks of age had significantly lower serum insulin concentrations and percent body fat compar

72 Fasting serum insulin concentrations differed among groups (F(33

73 etect genes influencing variation in fasting serum insulin concentrations in 391 nondiabetic individu

74 later life, and with lower blood glucose and serum insulin concentrations in infancy.

75 However, serum insulin concentrations provide an imprecise index

76 Profiles for blood glucose and serum insulin concentrations revealed higher peaks and l

77 Peak plasma glucose and serum insulin concentrations were greater after the HGI

78 However, remarkably decreased serum insulin concentrations were observed in Adipoq(-/-

79 Serum insulin concentrations were significantly increase

80 The cord-serum insulin concentrations were similar in the two gro

81 th the polycystic ovary syndrome, decreasing serum insulin concentrations with metformin reduces ovar

82 ycerides, 2-hour postload plasma glucose and serum insulin concentrations, and blood pressure.

83 ted in impaired glucose tolerance, increased serum insulin concentrations, and increased percent body

84 otein synthesis independently of a change in serum insulin concentrations.

85 ecrease in plasma glucose but did not affect serum insulin concentrations.

86 c diameter) and detecting the binding of MNP-serum insulin conjugate to the surface insulin-antibody

87 mit was further lowered to 5 pM by designing serum insulin conjugates with poly(acrylic acid)-functio

88 n 12-mo changes in weight, body composition, serum insulin, CRP, and 25(OH)D were compared between gr

89 clomiphene, the mean (+/-SE) area under the serum insulin curve after oral glucose administration de

90 metformin, the mean (+/- SE) area under the serum insulin curve after oral glucose administration de

91 Serum insulin decreased significantly in the SFD group,

92 Serum insulin decreased subsequent to the second meal at

93 uced but expression of Pepck increased while serum insulin decreased, glucose tolerance improved and

94 days in medium containing charcoal-stripped serum, insulin, epidermal growth factor, hepatocyte grow

95 Fasting blood sugar, serum insulin, fasting serum lipids and serum alanine am

96 Serum insulin, fatty acid, and triglyceride levels were

97 ic ATGL completely abrogated the increase in serum insulin following either 1 or 12 wk of feeding a h

98 disproportionately high level of circulating serum insulin for a given glucose concentration ( approx

99 Measured were serum insulin, free fatty acid (FFA), cortisol, and grow

100 in-sensitivity ChecK Index (QUICKI), fasting serum insulin (FSI), homeostasis model assessment of ins

101 into this phenotype, we show that, although serum insulin, glucose, and cholesterol levels are entir

102 are hyperphagic, and have elevated levels of serum insulin, glucose, and leptin.

103 During the fasting and postprandial periods, serum insulin, glucose, triacylglycerol, and nonesterifi

104 auterine growth restriction (IUGR) decreases serum insulin growth factor-1 (IGF-1) levels.

105 the development of hyperinsulinemia (fasting serum insulin > or = 90th percentile, 19.1 micro U/ml).

106 ancreatic cancer cells, and elevated fasting serum insulin has been linked to pancreatic cancer risk.

107 (omental and retroperitoneal), food intake, serum insulin, hepatic triglycerides or in the exercise-

108 essed the prognostic value of adding fasting serum insulin, HOMA-IR (homeostasis model assessment-ins

109 Fasting serum insulin, insulin-like growth factor I, fatty acids

110 rin is activated by pertussis toxin, whereas serum, insulin, insulin-like growth factor-1, and ligati

111 This is associated with increased serum insulin, islet insulin content, and insulin mRNA i

112 Body weight, serum insulin, leptin, glucose, cholesterol, and triglyc

113 Serum insulin level was associated with Barrett's esopha

114 y mass index but not with waist:hip ratio or serum insulin level.

115 blood glucose level and a marked rise in the serum insulin level.

116 tingly, LID mice show a fourfold increase in serum insulin levels (2.2 vs. 0.6 ng/ml in control mice)

117 veloped a time-dependent increase in fasting serum insulin levels (from 3.6 +/- 1.1 ng ml-1 at baseli

118 ent in glucose tolerance without a change in serum insulin levels and an increase in serum leptin lev

119 he formation of adenomas results in elevated serum insulin levels and decreased blood glucose levels.

120 body weight, as well as the normalization of serum insulin levels and glucose tolerance.

121 We observed reduced serum insulin levels and insulin-to-glucose ratios in hi

122 severe hyperglycemia with markedly decreased serum insulin levels and nearly normal insulin tolerance

123 Insulin infusion significantly increased serum insulin levels and the insulin/glucagon ratio.

124 Serum insulin levels are altered in insulin resistance a

125 tardation, mild hyperglycemia, and decreased serum insulin levels at 6 months of age when compared wi

126 n noted as a potential breast cancer marker (serum insulin levels being found to be raised in compari

127 We measured serum insulin levels by a validated radioimmunoassay, an

128 seven most strongly linked families had high serum insulin levels during fasting and 2-h post-glucose

129 Stable serum insulin levels during hyperglycemic clamping in pa

130 Intranasal insulin transiently increased serum insulin levels followed by a gradual lowering of b

131 Consistently, HGF concomitantly increased serum insulin levels in diabetic mice.

132 distinguishing the type of diabetes based on serum insulin levels in diabetic patients.

133 s associated with a significant reduction in serum insulin levels in fed and fasting mice.

134 Several studies have implicated serum insulin levels in the upregulation of leptin gene

135 In these subjects, the systemic serum insulin levels increased significantly during the

136 Among women higher fasting serum insulin levels increased the risk of gallbladder d

137 nt compared with control mice and had higher serum insulin levels on day 28.

138 th retardation and Turner syndrome; however, serum insulin levels were elevated.

139 Serum insulin levels were reduced in vivo in ritonavir-t

140 Serum insulin levels were significantly decreased in ani

141 Serum insulin levels were significantly different betwee

142 red first-phase insulin secretion, increased serum insulin levels, and greatly decreased levels of gl

143 induced hyperglycemia, a decrease in fasting serum insulin levels, and mild elevation of fasting seru

144 eficiency improves glucose tolerance, lowers serum insulin levels, and reduces TNFalpha gene expressi

145 , such as a reduced increase in body fat and serum insulin levels, compared to steroids.

146 um lipid, fasting serum glucose, and fasting serum insulin levels, or blood pressure.

147 tly improved glucose tolerance with enhanced serum insulin levels, reduced beta cell death, and incre

148 ition, Munc18c transgenic mice had depressed serum insulin levels, reflecting a threefold reduction i

149 ed by a 607 +/- 136 % (P < 0.01) increase in serum insulin levels.

150 to insulin and high fasting and postprandial serum insulin levels.

151 glycemia were associated with a decrease in serum insulin levels.

152 sponse to a glucose load in vivo, with lower serum insulin levels.

153 Serum insulin-like growth factor (IGF) -1 is secreted ma

154 ogenesis (4 months), the LF group had higher serum insulin-like growth factor (IGF) binding protein-1

155 Serum insulin-like growth factor (IGF)-I levels were dim

156 Clinical studies have established elevated serum insulin-like growth factor (IGF-I) content and IGF

157 ent epidemiologic studies unequivocally link serum insulin-like growth factor 1 (IGF-1) levels with r

158 te proliferation by modulating a decrease in serum insulin-like growth factor 1 (IGF-1) that allows G

159 Serum insulin-like growth factor 1 (IGF-1) was further r

160 smaller and had severely depressed levels of serum insulin-like growth factor 1 (IGF-1).

161 No difference in serum insulin-like growth factor 1 (IGF1) levels was obs

162 of in utero growth retardation, and had low serum insulin-like growth factor 1 (IGF1) levels.

163 Serum insulin-like growth factor 1 (IGF1) was not reduce

164 Serum insulin-like growth factor 1 levels and body weigh

165 ance and restored GH activation of STAT5 and serum insulin-like growth factor 1 levels in colitic mic

166 poor survival and postnatal growth with low serum insulin-like growth factor 1 levels.

167 rior cingulate, treatment-related changes in serum insulin-like growth factor 1 were positively corre

168 We also determined serum insulin-like growth factor binding protein-1 in fo

169 Serum insulin-like growth factor binding protein-1 level

170 Serum insulin-like growth factor binding protein-1 level

171 Serum insulin-like growth factor binding protein-1 level

172 receiver-operating-characteristic curve for serum insulin-like growth factor binding protein-1 was 0

173 ents with available measurements of baseline serum insulin-like growth factor binding protein-1.

174 Serum insulin-like growth factor I (IGF-I) levels consis

175 addition, there was about a 30% decrease in serum insulin-like growth factor I (IGF1), and while the

176 p also experienced a 10% greater increase in serum insulin-like growth factor I (P < 0.05) and a 16%

177 HR and GH binding protein, greatly decreased serum insulin-like growth factor I and elevated serum GH

178 higher serum alkaline phosphatase activity, serum insulin-like growth factor I and insulin-like grow

179 y corticosterone output, but only CR reduced serum insulin-like growth factor I and leptin.

180 ED decreased serum insulin-like growth factor I concentrations and in

181 for 18 months at a dose adjusted for normal serum insulin-like growth factor I level.

182 olic rate, nutrient and electrolyte balance, serum insulin-like growth factor I levels, D-xylose abso

183 ased urinary deoxypyridinoline and increased serum insulin-like growth factor I without affecting par

184 rease in marrow adiposity and a reduction in serum insulin-like growth factor-1 (IGF-1) and the bindi

185 fference (95% CI) was computed for levels of serum insulin-like growth factor-1 (IGF-1), leptin, and

186 zed panel of serologic testing that included serum insulin-like growth factor-1, insulin-like growth

187 axonal and neuropsychological recovery, and serum insulin-like growth factor-I (IGF-I) may mediate t

188 as drawn 0, 10, 20, and 40 days postburn and serum insulin-like growth factor-I (IGF-I), insulin-like

189 72%) weight, (iii) significant inhibition in serum insulin-like growth factor-I and restoration of in

190 nced growth hormone secretion, and increased serum insulin-like growth factor-I by threefold to sixfo

191 tochemical concentrate and green tea reduced serum insulin-like growth factor-I concentrations in bot

192 tudies individualising GH doses to normalize serum insulin-like growth factor-I level have shown a si

193 ROS, which was stimulated by growth factors (serum, insulin-like growth factor I, or fibroblast growt

194 free medium increased after 8 to 16 hours in serum, insulin-like growth factor-I (IGF-I), epidermal g

195 in the presence of nicotinamide, but with no serum, insulin-like growth factor-I or butyrate.

196 A combination of fetal calf serum, insulin-like growth factor-I, nicotinamide and so

197 achieved in vitro by addition of fetal calf serum, insulin-like growth factor-I, nicotinamide, and s

198 5 h of intravenous L-carnitine infusion with serum insulin maintained at fasting (7.4+/-0.4 mIU*l(-1)

199 nitoring, 10 patients had plasma glucose and serum insulin measurements, and 5 patients had repeated

200 nist CL 316,243 (CL) increased lipolysis and serum insulin more in KO mice, but blood glucose reducti

201 here were no abnormalities in serum glucose, serum insulin or the ability of insulin to stimulate glu

202 with winter season, waist circumference, and serum insulin (P < 0.005 for all).

203 0001), lower serum glucose (P = 0.04), lower serum insulin (P = 0.03), lower serum IL-(P = 0.0022), l

204 ne increased (P = 0.036) and correlated with serum insulin (r = 0.91, P = 0.002).

205 ely to be responsible, including much higher serum insulin responses to total parenteral nutrition th

206 Blood glucose and serum insulin returned to physiological levels during th

207 ants, LQT2 patients had 56% to 78% increased serum insulin, serum C-peptide, plasma GLP-1, and plasma

208 plant to assess fasting blood glucose (FBG), serum insulin (SI) levels, and i.v. glucose tolerance (I

209 plasma total fatty acid concentration, BMI, serum insulin, statin use, season, and longitudinal time

210 Serum insulin, thyroxine (T4), corticosterone, and adipo

211 tion in A-ZIP/F1 mice reduced blood glucose, serum insulin, triglyceride levels, and the rate of trig

212 knockout mice were not obese and had normal serum insulin, triglyceride, and leptin levels, with a t

213 Herein we report the first serum insulin voltammetric immunosensor for diagnosis of

214 Among nonusers of hormone therapy, fasting serum insulin was associated with a statistically signif

215 Serum insulin was decreased, and plasma glucagon was inc

216 vs 8.7 mmol/L [157 mg/dL] for placebo), and serum insulin was increased in the sulfonylurea studies

217 At Post, postprandial serum insulin was reduced in the Sedentary group (-49%;

218 RESULTS.: Blood glucose was the lowest and serum insulin was the highest in the islet+bone marrow g

219 Among the components of serum, insulin was identified as the key factor that mai

220 tration of uric acid, mean concentrations of serum insulin were 66.2, 66.7, 79.9, and 90.9 pmol/L for

221 and fed conditions, fat-free mass (FFM), and serum insulin were determined on the final day of each t

222 significant differences in plasma glucose or serum insulin were observed during exercise.

223 However, both basal and 2-h OGTT serum insulin were significantly correlated with SAT as

224 a activation in mature adipocytes normalizes serum insulin without increased adipogenesis.